I sold out of hznp as I got fed up with their practices; translated some of it into depo
(partly because it was so irresistibly attractive to Walbert, and depo looks to be on the rise
one way or another). Anyway, is the language re buyout on this board mainly noise or
are there real reasons to be looking for one?
Thx Sharon; I know the costs for current treatments are astronomical and Ral could be priced at less than half the cheapest current treatment and still make good $$ as it become adopted beyond recoup for orphan. But it's also looking more like there's a phase ii in strategy for these meds...
I've been confused as to how large the potential population for these meds is.
Those suffering from PAH per se comprise maybe less than 100k-- but can apd811
and relineapag (sp) address a larger population with hypertension?
In any case this follow-up candidate is a surprise to me-- and I hope they'll
partner the whole PAH franchise soon given the extra $$$$ here.
According to Yahoo stats more than 110% is owned by institutions + insiders, while ~20% is being borrowed by shorts: effectively twice owned by institutions. Even if only 5% is owned by indies, any real competition to cover shares will quickly result in an intense squeeze... on paper anyway.